RESECTABLE NSCLC
Clinical trials for RESECTABLE NSCLC explained in plain language.
Never miss a new study
Get alerted when new RESECTABLE NSCLC trials appear
Sign up with your email to follow new studies for RESECTABLE NSCLC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy aims to wipe out lung cancer before surgery
Disease control Recruiting nowThis study tests whether combining an immunotherapy drug (tislelizumab) with chest radiation before surgery can improve outcomes for people with early-stage lung cancer (NSCLC). About 20 participants will receive the combination, then have surgery to remove the tumor. The main go…
Matched conditions: RESECTABLE NSCLC
Phase: PHASE2 • Sponsor: Northern Jiangsu People's Hospital • Aim: Disease control
Last updated May 17, 2026 05:09 UTC
-
New triple therapy targets hard-to-treat lung cancer before surgery
Disease control Recruiting nowThis study tests a new approach for people with a certain genetic lung cancer (KRAS G12C mutation) that can be removed with surgery. Before surgery, patients receive a targeted pill (fulzerasib) for 6 weeks, then a 2-week break, followed by 3 cycles of immunotherapy (sintilimab) …
Matched conditions: RESECTABLE NSCLC
Phase: PHASE2 • Sponsor: Jianxing He • Aim: Disease control
Last updated May 11, 2026 20:51 UTC